{"DataElement":{"publicId":"7412933","version":"1","preferredName":"Procedure Administered Anti-cancer Therapy Type","preferredDefinition":"An indicator for the type of anti-cancer therapy administered.","longName":"PR_PRTRT_ACTX","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7412930","version":"1","preferredName":"Procedure Domain Procedure Administered","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure._Any stepwise set of actions._The act of having given something (e.g., a medication or test).","longName":"6407261v1.0:7412928v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6407261","version":"1","preferredName":"Procedure Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure.","longName":"C102700","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procedure Domain","conceptCode":"C102700","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73F3626C-19A3-3896-E053-F662850A4518","latestVersionIndicator":"Yes","beginDate":"2018-08-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-21","modifiedBy":"ONEDATA","dateModified":"2018-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7412928","version":"1","preferredName":"Procedure Administered","preferredDefinition":"Any stepwise set of actions.:The act of having given something (e.g., a medication or test).","longName":"C79751:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procedure","conceptCode":"C79751","definition":"Any stepwise set of actions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE8421D1-BA71-3A74-E053-4EBD850AC463","latestVersionIndicator":"Yes","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"ONEDATA","dateModified":"2020-09-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE8421D1-BA82-3A74-E053-4EBD850AC463","latestVersionIndicator":"Yes","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"SETRAKIN","dateModified":"2020-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7412931","version":"1","preferredName":"Anti-cancer Therapy Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"7412931v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE84262D-E8C6-3AD6-E053-4EBD850AC0A5","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"ONEDATA","dateModified":"2020-09-04","deletedIndicator":"No"},{"value":"External Beam Radiation Therapy","valueDescription":"External Beam Radiation Therapy","ValueMeaning":{"publicId":"5270692","version":"1","preferredName":"External Beam Radiation Therapy","longName":"5270692","preferredDefinition":"Radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"External Beam Radiation Therapy","conceptCode":"C15751","definition":"Radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3323451F-F576-38BE-E050-BB89AD430193","latestVersionIndicator":"Yes","beginDate":"2016-05-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-05-18","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE84262D-E8DA-3AD6-E053-4EBD850AC0A5","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"ONEDATA","dateModified":"2020-09-04","deletedIndicator":"No"},{"value":"Other Cellular Immunotherapy","valueDescription":"Cell Other Immunotherapy Cell Other Immunotherapy","ValueMeaning":{"publicId":"7412932","version":"1","preferredName":"Cell Other Immunotherapy Cell Other Immunotherapy","longName":"7412932","preferredDefinition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.: Different than the one(s) previously specified or mentioned.: Therapy designed to induce changes in a patient's immune status in order to treat disease.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.: Different than the one(s) previously specified or mentioned.: Therapy designed to induce changes in a patient's immune status in order to treat disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cell","conceptCode":"C12508","definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cell","conceptCode":"C12508","definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE84262D-E8EB-3AD6-E053-4EBD850AC0A5","latestVersionIndicator":"Yes","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"ONEDATA","dateModified":"2020-09-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE84262D-E904-3AD6-E053-4EBD850AC0A5","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"ONEDATA","dateModified":"2020-09-04","deletedIndicator":"No"},{"value":"CAR T-Cell Therapy","valueDescription":"Chimeric Antigen Receptor T-Cell Therapy","ValueMeaning":{"publicId":"7331413","version":"1","preferredName":"Chimeric Antigen Receptor T-Cell Therapy","longName":"7331413","preferredDefinition":"A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. Chimeric antigen receptor T-cell therapy is being studied in the treatment of some types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chimeric Antigen Receptor T-Cell Therapy","conceptCode":"C126102","definition":"Treatment that uses T-cells that have been engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D4A25B-396E-566A-E053-4EBD850AA9EA","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE84262D-E918-3AD6-E053-4EBD850AC0A5","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"ONEDATA","dateModified":"2020-09-04","deletedIndicator":"No"},{"value":"Immunotherapy (non-cellular)","valueDescription":"Immunotherapy","ValueMeaning":{"publicId":"5102332","version":"1","preferredName":"Immunotherapy","longName":"5102332","preferredDefinition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-01FA-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE84262D-E92C-3AD6-E053-4EBD850AC0A5","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"ONEDATA","dateModified":"2020-09-04","deletedIndicator":"No"},{"value":"HSCT","valueDescription":"Hematopoietic Cell Transplantation","ValueMeaning":{"publicId":"4395931","version":"1","preferredName":"Hematopoietic Cell Transplantation","longName":"4395931","preferredDefinition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEBB1E93-3F07-E882-E040-BB89AD431336","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-07-21","modifiedBy":"MMADDINENI","dateModified":"2024-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE84262D-E936-3AD6-E053-4EBD850AC0A5","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"ONEDATA","dateModified":"2020-09-04","deletedIndicator":"No"},{"value":"Chemotherapy","valueDescription":"Chemotherapy","ValueMeaning":{"publicId":"5102333","version":"1","preferredName":"Chemotherapy","longName":"5102333","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-0232-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE84262D-E940-3AD6-E053-4EBD850AC0A5","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"ONEDATA","dateModified":"2020-09-04","deletedIndicator":"No"},{"value":"Surgery","valueDescription":"Surgical Procedure","ValueMeaning":{"publicId":"3440172","version":"1","preferredName":"Surgical Procedure","longName":"3440172","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Surgical Procedure","conceptCode":"C15329","definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE12571D-0867-9ACA-E040-BB89AD4324C1","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-19","modifiedBy":"KUMMEROA","dateModified":"2024-02-22","changeDescription":"Added OBIB alternate name and identifier DW 03-21-2019","administrativeNotes":"2023.1.20 Alt VM added per ticket request CADSR0001943. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B86FDC77-D52B-0A71-E053-4EBD850A449E","beginDate":"2021-01-08","endDate":null,"createdBy":"GALITG","dateCreated":"2021-01-08","modifiedBy":"ONEDATA","dateModified":"2021-01-08","deletedIndicator":"No"},{"value":"Radiation Therapy","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2567129","version":"1","preferredName":"Radiation Therapy","longName":"2567129","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D346-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-21","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-10-21","modifiedBy":"KUMMEROA","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B86FDC77-D535-0A71-E053-4EBD850A449E","beginDate":"2021-01-08","endDate":null,"createdBy":"GALITG","dateCreated":"2021-01-08","modifiedBy":"ONEDATA","dateModified":"2021-01-08","deletedIndicator":"No"},{"value":"Other Non-Cellular Immunotherapy","valueDescription":"Other Immunotherapy","ValueMeaning":{"publicId":"7848154","version":"1","preferredName":"Other Immunotherapy","longName":"7848154","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Therapy designed to induce changes in a patient's immune status in order to treat disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D246E1A1-AD7E-1372-E053-4EBD850A5A99","latestVersionIndicator":"Yes","beginDate":"2021-12-03","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-12-03","modifiedBy":"ONEDATA","dateModified":"2021-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D246E1A1-AD97-1372-E053-4EBD850A5A99","beginDate":"2021-12-03","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-12-03","modifiedBy":"ONEDATA","dateModified":"2021-12-03","deletedIndicator":"No"},{"value":"Targeted Therapy","valueDescription":"Targeted Therapy","ValueMeaning":{"publicId":"3623150","version":"1","preferredName":"Targeted Therapy","longName":"3623150","preferredDefinition":"A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Targeted Therapy","conceptCode":"C93352","definition":"A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CCB54008-9077-E649-E040-BB89AD436CAF","latestVersionIndicator":"Yes","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D246E1A1-ADA1-1372-E053-4EBD850A5A99","beginDate":"2021-12-03","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-12-03","modifiedBy":"ONEDATA","dateModified":"2021-12-03","deletedIndicator":"No"},{"value":"Monoclonal Antibody Therapy","valueDescription":"Monoclonal Antibody Therapy","ValueMeaning":{"publicId":"8029598","version":"1","preferredName":"Monoclonal Antibody Therapy","longName":"8029598","preferredDefinition":"Monoclonal Antibody Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7773850-70AB-1FF0-E053-4EBD850A3D2F","latestVersionIndicator":"Yes","beginDate":"2022-02-07","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-02-07","modifiedBy":"ONEDATA","dateModified":"2022-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D7773850-70C4-1FF0-E053-4EBD850A3D2F","beginDate":"2022-02-07","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-02-07","modifiedBy":"ONEDATA","dateModified":"2022-02-07","deletedIndicator":"No"},{"value":"Blinatumomab","valueDescription":null,"ValueMeaning":{"publicId":"3690103","version":"1","preferredName":"Blinatumomab","longName":"3690103","preferredDefinition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E36-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3A5A82E-C452-5386-E053-731AD00A28BE","beginDate":"2023-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-01","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","deletedIndicator":"No"},{"value":"Inotuzumab","valueDescription":null,"ValueMeaning":{"publicId":"5577157","version":"1","preferredName":"Inotuzumab Ozogamicin","longName":"5577157","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-09D6-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3A5A82E-C453-5386-E053-731AD00A28BE","beginDate":"2023-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-01","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","deletedIndicator":"No"},{"value":"TKI","valueDescription":null,"ValueMeaning":{"publicId":"5127433","version":"1","preferredName":"Tyrosine Kinase Inhibitor","longName":"5127433","preferredDefinition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FB7E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F3A5A82E-C454-5386-E053-731AD00A28BE","beginDate":"2023-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-01","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","deletedIndicator":"No"},{"value":"Allogeneic Stem Cell Transplant","valueDescription":null,"ValueMeaning":{"publicId":"2688157","version":"1","preferredName":"Allogeneic Hematopoietic Stem Cell Transplantation","longName":"2688157","preferredDefinition":"A clinical treatment in which HSC capable of reconstituting the immune system and blood production (hematopoiesis) are transferred from one genetically dissimilar individual to another. The donor and recipient may or may not be related. 2005","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allogeneic Hematopoietic Stem Cell Transplantation","conceptCode":"C46089","definition":"A clinical treatment in which hematopoietic stem cells (HSCs) are transferred from one genetically dissimilar individual to another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C02704A-A3F4-6131-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-08","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-10-08","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F71CC3CC-7A3E-65E0-E053-731AD00A845D","beginDate":"2023-03-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-17","modifiedBy":"KUMMEROA","dateModified":"2023-03-17","deletedIndicator":"No"},{"value":"Autologous Stem Cell Transplant","valueDescription":null,"ValueMeaning":{"publicId":"2688156","version":"1","preferredName":"Autologous Stem Cell Transplantation","longName":"2688156","preferredDefinition":"The transference of stem cells within the same individual.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous Hematopoietic Stem Cell Transplantation","conceptCode":"C16039","definition":"Stem cell transfer or transplantation in which the patient is their own donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C02704A-A3CF-6131-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-08","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-10-08","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F71CC3CC-7A3F-65E0-E053-731AD00A845D","beginDate":"2023-03-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-17","modifiedBy":"KUMMEROA","dateModified":"2023-03-17","deletedIndicator":"No"},{"value":"Brentuximab Vedotin","valueDescription":null,"ValueMeaning":{"publicId":"3228385","version":"1","preferredName":"Brentuximab Vedotin","longName":"3228385","preferredDefinition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16046E6-D6A0-1B8D-E040-BB89AD434ADA","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F71CC3CC-7A40-65E0-E053-731AD00A845D","beginDate":"2023-03-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-17","modifiedBy":"KUMMEROA","dateModified":"2023-03-17","deletedIndicator":"No"},{"value":"Tisagenlecleucel","valueDescription":null,"ValueMeaning":{"publicId":"13274846","version":"1","preferredName":"Tisagenlecleucel","longName":"13274846v1.00","preferredDefinition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tisagenlecleucel","conceptCode":"C102758","definition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F813ED9F-97F0-49D9-E053-731AD00A9AD0","latestVersionIndicator":"Yes","beginDate":"2023-03-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-29","modifiedBy":"GDEEN","dateModified":"2023-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F813DED0-B451-47B4-E053-731AD00A0624","beginDate":"2023-03-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-29","modifiedBy":"GDEEN","dateModified":"2023-03-29","deletedIndicator":"No"},{"value":"Imatinib","valueDescription":null,"ValueMeaning":{"publicId":"3228378","version":"1","preferredName":"Imatinib","longName":"3228378","preferredDefinition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib","conceptCode":"C62035","definition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A160434C-66D5-A92B-E040-BB89AD43423D","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F813DED0-B452-47B4-E053-731AD00A0624","beginDate":"2023-03-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-29","modifiedBy":"GDEEN","dateModified":"2023-03-29","deletedIndicator":"No"},{"value":"Dasatinib","valueDescription":null,"ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F813DED0-B453-47B4-E053-731AD00A0624","beginDate":"2023-03-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-29","modifiedBy":"GDEEN","dateModified":"2023-03-29","deletedIndicator":"No"},{"value":"Nilotinib","valueDescription":null,"ValueMeaning":{"publicId":"5805905","version":"1","preferredName":"Nilotinib","longName":"5805905","preferredDefinition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib","conceptCode":"C48375","definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA044AC-B549-3351-E053-F662850A8B45","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F813DED0-B454-47B4-E053-731AD00A0624","beginDate":"2023-03-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-29","modifiedBy":"GDEEN","dateModified":"2023-03-29","deletedIndicator":"No"},{"value":"Ponatinib","valueDescription":null,"ValueMeaning":{"publicId":"3776076","version":"1","preferredName":"Ponatinib","longName":"3776076","preferredDefinition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ponatinib","conceptCode":"C95777","definition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DC57-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F813DED0-B455-47B4-E053-731AD00A0624","beginDate":"2023-03-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-29","modifiedBy":"GDEEN","dateModified":"2023-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE84262D-E8AF-3AD6-E053-4EBD850AC0A5","latestVersionIndicator":"Yes","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"GDEEN","dateModified":"2023-03-29","changeDescription":null,"administrativeNotes":"2023.3.17 PVs added per ticket request CADSR0002164. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"PR_PRTRT_OTHACTX","type":"COG Form Element","context":"COG"},{"name":"PR_PRTRT_CART","type":"COG Form Element","context":"COG"},{"name":"PR_PRTRT_CHEMOTHERAPY","type":"COG Form Element","context":"COG"},{"name":"PR_PRTRT_EBRT","type":"COG Form Element","context":"COG"},{"name":"PR_PRTRT_HSCT","type":"COG Form Element","context":"COG"},{"name":"PR_PRTRT_IMMUNOTHERAPY","type":"COG Form Element","context":"COG"},{"name":"PR_PRTRT_OCI","type":"COG Form Element","context":"COG"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"PR_PRTRT_ACTX_DASA","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"Anti-cancer therapy:","type":"Preferred Question Text","description":"Anti-cancer therapy:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Type(s) of anti-cancer therapy the patient received:","url":null,"context":"COG"},{"name":"COG CRF Text 02","type":"Alternate Question Text","description":"What type of leukemia directed therapy did the patient receive?","url":null,"context":"COG"},{"name":"COG CRF Text 03","type":"Alternate Question Text","description":"Type(s) of leukemia directed therapy the patient received:","url":null,"context":"COG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Type of anti-cancer therapy:","url":null,"context":"COG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Dasatinib","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE85FACF-7730-4EDE-E053-4EBD850AAE40","latestVersionIndicator":"Yes","beginDate":"2020-09-04","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-04","modifiedBy":"KUMMEROA","dateModified":"2023-06-29","changeDescription":null,"administrativeNotes":"2023.6.29 AQT/Alt SN added per ticket request CADSR0002564. ak 2023.3.17 AQT added per ticket request CADSR0002164. ak","unresolvedIssues":null,"deletedIndicator":"No"}}